Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salvia miltiorrhiza Bunge crude extract (DCE), also known as Danshen extract, is an herbal preparation derived from the roots of the Salvia miltiorrhiza plant. It is being investigated for its potential therapeutic application in glioblastoma multiforme (GBM). DCE exhibits anticancer activity by inducing G0/G1 cell cycle arrest and promoting apoptosis in GBM cell lines. Its mechanism of action involves the modulation of the tumor microenvironment through the downregulation of pro-inflammatory signaling pathways, specifically the IL-17, NF-κB, and TNF pathways. This results in the decreased expression of key genes such as CXCL2, CXCL3, CXCL8 (IL-8), and PTGS2 (COX-2). Preclinical studies in U87-MG xenograft models have demonstrated that DCE significantly suppresses tumor growth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salvia miltiorrhiza bunge crude extract.